Licheng Shi

Title: Licheng Shi: Innovator in CGRP Receptor Binding Proteins

Introduction

Licheng Shi is a prominent inventor based in Newbury Park, California. He has made significant contributions to the field of biotechnology, particularly in the development of antigen binding proteins that target the human CGRP receptor. With a total of four patents to his name, his work has the potential to impact the treatment of various disorders.

Latest Patents

Licheng Shi's latest patents focus on human CGRP receptor binding proteins. These antigen binding proteins are designed to bind to the human CGRP receptor (CGRP R). The patents also include nucleic acids encoding the antigen binding proteins, as well as vectors and cells that express these proteins. Notably, these antigen binding proteins can inhibit the binding of CGRP R to CGRP, making them useful in treating and preventing migraine headaches and other CGRP R related disorders.

Career Highlights

Licheng Shi is currently employed at Amgen Inc., a leading biotechnology company. His work at Amgen has allowed him to further his research and development efforts in the field of receptor binding proteins. His innovative approach and dedication to advancing medical science have positioned him as a key figure in his area of expertise.

Collaborations

Licheng Shi has collaborated with notable colleagues, including Thomas Charles Boone and David W Brankow. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic solutions.

Conclusion

Licheng Shi's contributions to the field of biotechnology, particularly in the development of CGRP receptor binding proteins, highlight his innovative spirit and commitment to improving healthcare. His work has the potential to lead to significant advancements in the treatment of migraine headaches and related disorders.